The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.
about
The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysisOsteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone LossPathogenesis of apical periodontitis: a literature reviewThe pathobiology and pathology of aseptic implant failureReduction of particle-induced osteolysis by interleukin-6 involves anti-inflammatory effect and inhibition of early osteoclast precursor differentiationAge of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.Do tissues from THA revision of highly crosslinked UHMWPE liners contain wear debris and associated inflammation?Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.Role of polyethylene particles in peri-prosthetic osteolysis: A review.Combination gene therapy targeting on interleukin-1β and RANKL for wear debris-induced aseptic loosening.Periodontitis and rheumatoid arthritis: a review.Novel host response therapeutic approaches to treat periodontal diseases.The central role of wear debris in periprosthetic osteolysis.In Vitro Cytokine Expression and In Vivo Healing and Inflammatory Response to a Collagen-Coated Synthetic Bone Filler.Genetic susceptibility to hip arthroplasty failure--association with the RANK/OPG pathwayProspective analysis of human leukocyte functional tests reveals metal sensitivity in patients with hip implantPolymethylmethacrylate particles stimulate bone resorption of mature osteoclasts in vitro.Effects of ginsenosides rg1 on osteoblasts cultured with ti particles.The combined role of wear particles, macrophages and lymphocytes in the loosening of total joint prosthesesRANKL inhibition for the management of patients with benign metabolic bone disorders.Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management.BMP-2 and titanium particles synergistically activate osteoclast formationEffects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.Role of macrophages in the biological reaction to wear debris from joint replacements.Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane.The Effect of RANKL/OPG Balance on Reducing Implant Complications.High levels of substance P and CGRP in pseudosynovial fluid from patients with aseptic loosening of their hip prosthesis.Biological effects of metal degradation in hip arthroplasties.Osteoclasts and their precursors are present in the induced-membrane during bone reconstruction using the Masquelet technique.Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.
P2860
Q22000865-E11202A5-B387-4334-A7C5-66C77B2972EDQ27008993-1DEB97A0-81A5-466B-BDD0-E1603A90A050Q27014161-0F2A0958-DD06-4F92-AE93-F83EE3D7D42FQ28828900-B696E42E-564A-418A-8F50-AB3400AE5CA1Q33946711-ED96D234-B854-450E-B384-7D46DB199814Q34667359-C4615A9D-C037-4ECB-B2E6-0797D8D6B600Q35078832-A33E6E3C-8780-4F74-9A93-98ED1BC5140BQ35551233-F4ADC604-1C27-4985-BF3A-12E5A7CDE8A7Q35825373-14D15920-19E2-4BDB-921C-3A4D8B9457A6Q35951712-03263873-9F46-4662-9C8E-F0884421712DQ36309246-4872D9EA-12E1-429B-ACFB-B4AEDF177A0EQ36703987-B2385DFF-D743-474D-9624-C530146BBBADQ36796472-55DC2103-5830-4B4F-A7CC-5B5491652FBAQ36855459-6EB836F9-9979-48E7-8088-36B841DA0973Q36867041-14B1CEE1-5507-48C8-946D-D1634224B876Q36908606-D2BF258D-0C55-4023-A6EC-84C7E1E0A53CQ37142926-14B5EF93-8886-4AA7-BDDD-7E04CA9FD912Q37219405-670165EF-83CB-4FC5-AAFF-AB5482C246C5Q37224018-136E93CF-05DA-4FB7-A67D-6EF7D9ADA527Q37532561-3F98E640-3965-429D-9E74-A6C3D5BF79C9Q38152730-2D987075-5CE4-4AB4-986B-9FCD2339D315Q38995801-C5E0079E-8882-4B5A-B499-499A6EAC8B46Q40534131-79E3CC32-EA30-43DD-BF43-885FA393821AQ42109325-E28F46C0-588A-4021-9AFB-667F794CCE43Q42755979-7D0B197B-BDD3-4F11-ABE6-2B67C64B9923Q43573612-E03C5C6C-79A4-41E1-B96B-B4EEB19D4A7EQ47167957-C8352FFC-5BA5-4019-B699-34C0D8207F46Q47578201-F1E1988B-CB1F-4BC1-BB04-07CEAF6171B0Q47610061-67088CA1-13D0-4DAF-A079-2189CF46BF16Q50469054-4EFC1109-499D-4E72-AC40-77195682A7CAQ51355256-1EABB71D-BC97-4E5D-AABB-8425DC4FB4DB
P2860
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@ast
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@en
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@nl
type
label
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@ast
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@en
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@nl
prefLabel
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@ast
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@en
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@nl
P2093
P1476
The osteoclastogenic molecules ...... ith periprosthetic osteolysis.
@en
P2093
Findlay DM
P304
P356
10.1302/0301-620X.83B6.10905
P577
2001-08-01T00:00:00Z